Can a simple test predict immunotherapy outcomes for pancreatic cancer?

NCT ID NCT07271823

Ongoing Knowledge-focused Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to develop a way to predict which patients with advanced pancreatic cancer will respond to immunotherapy. Researchers will collect tumor tissue, blood, and stool samples from 100 participants before and during treatment. By analyzing these samples, they hope to create a model that forecasts treatment response, potentially personalizing cancer care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which pancreatic cancer patients will benefit from immunotherapy, leading to more personalized and effective treatment plans.
What could go wrong: This is an early observational study, not a treatment trial. The predictive model may not be accurate enough for clinical use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER NON-RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER NON-RESECTABLE

Contacts and locations

Locations

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

Zhejiang, Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.